Pateclizumab

From WikiMD's WELLNESSPEDIA

Pateclizumab is a monoclonal antibody that was designed for the treatment of rheumatoid arthritis. It was developed by Genentech, a biotechnology company based in the United States. Pateclizumab targets the interleukin 6 (IL-6) pathway, which plays a crucial role in the inflammatory response that characterizes rheumatoid arthritis.

Mechanism of Action[edit]

Pateclizumab works by binding to the interleukin 6 receptor (IL-6R), thereby inhibiting the interaction between IL-6 and its receptor. This prevents the activation of the IL-6 pathway, which is known to contribute to the inflammation and joint damage seen in rheumatoid arthritis.

Clinical Trials[edit]

Pateclizumab has undergone Phase II clinical trials for the treatment of rheumatoid arthritis. The results of these trials showed that pateclizumab was well-tolerated and led to improvements in disease activity scores in patients with rheumatoid arthritis.

See Also[edit]

References[edit]

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.